BioCorRx (BICX) Common Equity (2010 - 2026)

BioCorRx has reported Common Equity for 17 years, with the latest figure at -$180813.0 in Q1 2026.

• Quarterly Common Equity rose 98.47% year-over-year to -$180813.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$180813.0 (up 98.47% YoY) and the FY2025 annual result came in at -$11.5 million, up 6.7% from the prior year.
• Common Equity improved to -$180813.0 in Q1 2026 per BICX's latest filing, from -$11.5 million in the prior quarter.
• Over five years, Common Equity peaked at $5616.0 in Q3 2025 and troughed at -$12.4 million in Q4 2024.
• A 5-year average of -$8.5 million and a median of -$9.0 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity tumbled 93.72% in 2022, then surged 100.05% in 2025.
• Over 5 years, Common Equity stood at -$8.2 million in 2022, then dropped by 21.35% to -$10.0 million in 2023, then slipped by 24.14% to -$12.4 million in 2024, then increased by 6.7% to -$11.5 million in 2025, then surged by 98.43% to -$180813.0 in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$180813.0, -$11.5 million, and $5616.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.